Zug, Switzerland, June 22, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that the company will host a scientific symposium on acute hearing loss at the 21st IFOS ENT World Congress in Paris. The symposium titled "Recent Advances in the Treatment of Acute Hearing Loss" will feature several experts in the field of hearing loss research. The event will take place on Monday, June 26, 2017, at 12:30 pm CEST. Following the symposium, the presentation will be available in the Events & Presentations section of the Auris Medical website at www.aurismedical.com.
The IFOS ENT World Congress is held every three years and is the largest international conference in the ear, nose and throat medical specialty. It is organized by the International Federation of Oto-Rhino-Laryngological Societies (IFOS).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, firstname.lastname@example.org
Media contact: David Schull, Russo Partners, 1-858-717-2310,
Auris Medical AG